Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.

Przuntek, Horst; Bittkau, Stefan; Bliesath, Harald; Büttner, Ulrich; Fuchs, Gerd; Glass, Joachim; Haller, Harald; Klockgether, Thomas; Kraus, Peter; Lachenmayer, Lutz; Müller, Dieter; Müller, Thomas; Rathay, Bernhard; Sgonina, Jörg; Steinijans, Volker; Teshmar, Elemer; Ulm, Gudrun; Volc, Dieter

Przuntek, Horst; Bittkau, Stefan; Bliesath, Harald; Büttner, Ulrich; Fuchs, Gerd; Glass, Joachim; Haller, Harald; Klockgether, Thomas; Kraus, Peter; Lachenmayer, Lutz; Müller, Dieter; Müller, Thomas; Rathay, Bernhard; Sgonina, Jörg; Steinijans, Volker; Teshmar, Elemer; Ulm, Gudrun; Volc, Dieter.

Affiliation

Przuntek H; Department of Neurology, Ruhr University of Bochum, Gudrunstrass 56, 44791 Bochum, Germany. Horst.Przuntek@ruhr-uni-bochum.de

Arch Neurol ; 59(5): 803-6, 2002 May.

Article in En | MEDLINE | ID: mdl-12020263

Subject(s)

Antiparkinson Agents/therapeutic use; Dopamine Agents/therapeutic use; Levodopa/therapeutic use; Parkinson Disease/drug therapy; Piperidines/therapeutic use; Adult; Aged; Bromocriptine/therapeutic use; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Treatment Outcome

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Parkinson Disease / Piperidines / Dopamine Agents / Levodopa / Antiparkinson Agents Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2002 Type: Article

Search on Google

XML

PubMed Links